Altium Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Altium Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-133,333	Closed	-$4.82K	–	107
2023 Q1	$4.82K	Hold	133,333	–	–	﹤0.01%	85
2022 Q4	$7.41K	Hold	133,333	–	–	﹤0.01%	88
2022 Q3	$5K	Hold	133,333	–	–	﹤0.01%	127
2022 Q2	$9K	Hold	133,333	–	–	﹤0.01%	119
2022 Q1	$25K	Hold	133,333	–	–	0.01%	110
2021 Q4	$77K	Hold	133,333	–	–	0.02%	123
2021 Q3	$107K	Hold	133,333	–	–	0.03%	114
2021 Q2	$139K	Buy	+133,333	New	+$120K	0.03%	130

Altium Capital Management's EUCRW Position: Q2 2023 in Review

Altium Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 133,333 shares — an estimated $4.82K sold.

Altium Capital Management first reported a position in EUCRW in Q2 2021 and held it in 8 quarters. The position peaked at $139K in Q2 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Altium Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Altium Capital Management sold 133,333 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $4.82K.
Altium Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2021 and held it in 8 quarters.
Altium Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $139K in Q2 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.